Development of a HIV-1 vaccine using an orally-administered, replication-competent adenovirus serotype 4 vector expressing Env clade C glycoprotein
| Autor: | Marc Gurwith, Tim Mayall, Jenny B. Avanzini, David C. Montefiori, Jason Mendy, Barton F. Haynes, Darly J. Manayani, L Vang, Hua-Xin Liao, Peggy Farness, B Guenther, Jeff Alexander, Celia C. LaBranche |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
lcsh:Immunologic diseases. Allergy
Influenza vaccine viruses medicine.disease_cause 03 medical and health sciences Virology Medicine Vector (molecular biology) 030304 developmental biology chemistry.chemical_classification 0303 health sciences biology 030306 microbiology business.industry Hiv 1 vaccine Immunogenicity virus diseases Influenza A virus subtype H5N1 3. Good health Infectious Diseases chemistry Poster Presentation biology.protein Antibody business Glycoprotein lcsh:RC581-607 Adenovirus serotype |
| Zdroj: | Retrovirology, Vol 9, Iss Suppl 2, p P35 (2012) Retrovirology |
| ISSN: | 1742-4690 |
| Popis: | Background Our hypothesis is that the replicating Ad4 vector approach, may be the best strategy for an effective HIV-1 vaccine due to advantages of demonstrated clinical safety and immunogenicity of both the Ad4 backbone and an Ad4 H5N1 vector influenza vaccine evaluated in Phase 1. Unlike other vectors, it can be bioengineered to express full-length HIV-1 Env gp160. More than 50% of global HIV-1 infections are caused by clade C viruses and therefore we initiated development of Ad4-Env160 vaccine using an Env clade C sequence obtained from CHAVI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink